Osinertinib is a medication used in targeted therapy for certain types of non-small cell lung cancer (NSCLC). It’s an oral medication that targets specific mutations in the epidermal growth factor receptor (EGFR) gene, which are common in NSCLC. Osimertinib works by blocking the activity of mutated EGFR proteins, thereby slowing down or stopping the growth of cancer cells. It’s typically prescribed for patients with NSCLC that has specific EGFR mutations and has progressed despite other treatments. Osimertinib mesylate 80 mg is a medication used in targeted therapy for certain types of non-small cell lung cancer (NSCLC). It’s an oral medication that targets specific mutations in the epidermal growth factor receptor (EGFR) gene, which are common in NSCLC. Osimertinib works by blocking the activity of mutated EGFR proteins, thereby slowing down or stopping the growth of cancer cells. It’s typically prescribed for patients with NSCLC that has specific EGFR mutations and has progressed despite other treatments.

Olaparib is a medication used in targeted therapy for certain types of cancer, particularly ovarian and breast cancer. It belongs to a class of drugs called PARP inhibitors, which work by blocking the activity of poly (ADP-ribose) polymerase (PARP) enzymes. PARP enzymes help repair damaged DNA in cells, including cancer cells. By inhibiting PARP, Olaparib prevents cancer cells from repairing their DNA, leading to their death. It’s often used in patients with ovarian or breast cancer who have specific genetic mutations, such as BRCA1 or BRCA2 mutations, and have either recurrent or advanced disease. Olaparib is a medication used in targeted therapy for certain types of cancer, particularly ovarian and breast cancer. It belongs to a class of drugs called PARP inhibitors, which work by blocking the activity of poly (ADP-ribose) polymerase (PARP) enzymes. PARP enzymes help repair damaged DNA in cells, including cancer cells. By inhibiting PARP, Olaparib prevents cancer cells from repairing their DNA, leading to their death. It’s often used in patients with ovarian or breast cancer who have specific genetic mutations, such as BRCA1 or BRCA2 mutations, and have either recurrent or advanced disease.

Niraparib is a medication used in targeted therapy for certain types of cancer, particularly ovarian cancer. It belongs to a class of drugs called PARP inhibitors, which work by blocking the activity of poly (ADP-ribose) polymerase (PARP) enzymes. PARP enzymes help repair damaged DNA in cells, including cancer cells. By inhibiting PARP, niraparib prevents cancer cells from repairing their DNA, leading to their death. Niraparib is often used as maintenance therapy in patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy, helping to delay disease progression. It may also be used in other types of cancer with specific genetic mutations.

Palbociclib is a medication used in targeted therapy for certain types of breast cancer. It belongs to a class of drugs called CDK4/6 inhibitors, which work by inhibiting cyclin-dependent kinases 4 and 6, enzymes involved in cell cycle regulation. Palbociclib helps to slow down or stop the growth of cancer cells by interfering with their ability to divide and proliferate. It’s often used in combination with other medications, such as hormonal therapies, for the treatment of hormone receptor-positive, HER2- negative advanced breast cancer in postmenopausal women or in men. Palbociclib is a medication used in targeted therapy for certain types of breast cancer. It belongs to a class of drugs called CDK4/6 inhibitors, which work by inhibiting cyclin-dependent kinases 4 and 6, enzymes involved in cell cycle regulation. Palbociclib helps to slow down or stop the growth of cancer cells by interfering with their ability to divide and proliferate. It’s often used in combination with other medications, such as hormonal therapies, for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women or in men.

Lenvatinib is a medication used in targeted therapy for certain types of cancer, particularly thyroid cancer and kidney cancer. It belongs to a class of drugs called receptor tyrosine kinase inhibitors, which work by blocking the activity of multiple receptors involved in tumor growth and progression, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR), among others. By inhibiting these receptors, lenvatinib helps to slow down or stop the growth of blood vessels that supply tumors with nutrients and oxygen, thereby suppressing tumor growth. It’s often used in combination with other medications or as monotherapy for the treatment of advanced or metastatic thyroid or kidney cancer. Lenvatinib is a medication used in targeted therapy for certain types of cancer, particularly thyroid cancer and kidney cancer. It belongs to a class of drugs called receptor tyrosine kinase inhibitors, which work by blocking the activity of multiple receptors involved in tumor growth and progression, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR), among others. By inhibiting these receptors, lenvatinib helps to slow down or stop the growth of blood vessels that supply tumors with nutrients and oxygen, thereby suppressing tumor growth. It’s often used in combination with other medications or as monotherapy for the treatment of advanced or metastatic thyroid or kidney cancer.

Lorlatinib is a medication used in targeted therapy for certain types of non-small cell lung cancer (NSCLC), particularly those with specific genetic mutations. It belongs to a class of drugs called ALK inhibitors, which work by targeting and blocking the activity of an abnormal protein called anaplastic lymphoma kinase (ALK). ALK mutations are found in some NSCLC tumors, and drugs like lorlatinib can help slow down or stop the growth of cancer cells that have these mutations. Lorlatinib is often used when NSCLC has progressed despite other treatments or when it has spread to other parts of the body. Lorlatinib is a medication used in targeted therapy for certain types of non-small cell lung cancer (NSCLC), particularly those with specific genetic mutations. It belongs to a class of drugs called ALK inhibitors, which work by targeting and blocking the activity of an abnormal protein called anaplastic lymphoma kinase (ALK). ALK mutations are found in some NSCLC tumors, and drugs like lorlatinib can help slow down or stop the growth of cancer cells that have these mutations. Lorlatinib is
often used when NSCLC has progressed despite other treatments or when it has spread to other parts of the body.

Ponatinib is a medication used in targeted therapy for a specific type of leukemia called chronic myeloid leukemia (CML) and a rare type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking the activity of an abnormal protein called BCR-ABL tyrosine kinase. This protein is produced by a genetic abnormality known as the Philadelphia chromosome, which is commonly found in CML and Ph+ ALL. By inhibiting BCR-ABL tyrosine kinase, ponatinib helps to slow down or stop the growth of leukemia cells. It’s typically used when other treatments have not been effective or when the disease has progressed despite other therapies. Ponatinib is a medication used in targeted therapy for a specific type of leukemia called chronic myeloid leukemia (CML) and a rare type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking the activity of an abnormal protein called BCR-ABL tyrosine kinase. This protein is produced by a genetic abnormality known as the Philadelphia chromosome, which is commonly found in CML and Ph+ ALL. By inhibiting BCR-ABL tyrosine kinase, ponatinib helps to slow down or stop the growth of leukemia cells. It’s typically used when other treatments have not been effective or when the disease has progressed despite other therapies.

Ibrutinib is a medication used in targeted therapy for certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and marginal zone lymphoma. It belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors, which work by blocking the activity of BTK, a protein involved in the survival and growth of cancerous B cells. By inhibiting BTK, ibrutinib helps to slow down or stop the growth and spread of cancer cells in these types of lymphomas and leukemias. It’s often used as a first-line or subsequent therapy, depending on the specific type of cancer and individual patient factors.

Larotrectinib is a medication used in targeted therapy for cancers that have specific genetic alterations known as NTRK fusions. These fusions involve the rearrangement of the NTRK genes, leading to the production of abnormal TRK proteins that promote cancer growth. Larotrectinib is a selective inhibitor of these abnormal TRK proteins, thereby helping to inhibit cancer growth in patients with NTRK fusion- positive cancers. It’s approved for the treatment of various solid tumors across different age groups, including pediatric and adult patients, who have these specific genetic alterations. Larotrectinib has shown promising results in clinical trials, often leading to durable responses in patients with NTRK fusion-positive cancers.